Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis - Poll - MDSpire

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • By

  • Sharlene Dong

  • Rahul Banerjee

  • Adeel M. Khan

  • Mengru Wang

  • Xiaoliang Wang

  • Anosheh Afghahi

  • Aimaz Afrough

  • Murali Janakiram

  • Bo Wang

  • Andrew J. Cowan

  • Adam S. Sperling

  • Larry D. Anderson

  • S. Vincent Rajkumar

  • Gurbakhash Kaur

  • March 28, 2025

  • 0 min

Share

Original Source(s)

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • by Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur

  • March 28, 2025

Related Content

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications